# OnCo record destiny-gastric02 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/destiny-gastric02/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "destiny-gastric02", "NCT04014075" ;
  schema:name "DESTINY-Gastric02"@en ;
  schema:description "DESTINY-Gastric02 repeated the trastuzumab deruxtecan study in patients from Europe and the United States, after the first trial had been run only in Japan and Korea, and confirmed that the drug produces meaningful responses in HER2-positive stomach cancer after trastuzumab."@en ;
  schema:url <https://onco.cc/trials/destiny-gastric02/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04014075> ;
  onco:status "completed" ;
  onco:tag "subtype-trials" ;
  onco:phase "2" ;
  onco:cancers <https://onco.cc/cancers/gastric-her2-positive/>, <https://onco.cc/cancers/gastric/> ;
  onco:drugs <https://onco.cc/drugs/trastuzumab-deruxtecan/> ;
  onco:companies <https://onco.cc/companies/daiichi-sankyo/>, <https://onco.cc/companies/astrazeneca/> ;
  onco:people <https://onco.cc/people/eric-van-cutsem/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-destiny-gastric01-nejm-2020/> .